M. Özgüroğlu

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2019, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Durvalumab plus platinum–etoposide versus platinum–etoposide in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): a randomised, controlled, open-label, phase 3 trial

Young Hak Kim, N. Reinmuth, A. Chiang, 2019, The Lancet.

Outcomes with durvalumab by tumour PD-L1 expression in unresectable, Stage III non-small-cell lung cancer in the PACIFIC trial.

D. Planchard, C. Faivre-Finn, S. Senan, 2020, Annals of oncology : official journal of the European Society for Medical Oncology.

Osimertinib Maintenance After Definitive Chemoradiation in Patients With Unresectable EGFR Mutation Positive Stage III Non-small-cell Lung Cancer: LAURA Trial in Progress.

S. Ramalingam, M. Saggese, Shun Lu, 2021, Clinical lung cancer.

Brief report: Four-year survival with durvalumab after chemoradiotherapy in Stage III NSCLC - an update from the PACIFIC trial.

Yi-long Wu, D. Planchard, C. Faivre-Finn, 2020, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

Characterizing immune-mediated adverse events with durvalumab in patients with unresectable stage III NSCLC: A post-hoc analysis of the PACIFIC trial.

C. Faivre-Finn, J. Vansteenkiste, J. Naidoo, 2022, Lung cancer.

Avelumab vs docetaxel in patients with platinum-treated advanced non-small-cell lung cancer: 2-year follow-up from the JAVELIN Lung 200 phase 3 trial.

Keunchil Park, F. de Marinis, M. Krzakowski, 2021, Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer.

378MO EMPOWER-Lung 1: Phase III first-line (1L) cemiplimab monotherapy vs platinum-doublet chemotherapy (chemo) in advanced non-small cell lung cancer (NSCLC) with programmed cell death-ligand 1 (PD-L1) ≥50%

I. Lowy, V. Sriuranpong, P. Clingan, 2020, Annals of Oncology.

PL02.11 Overall Survival with Durvalumab Plus Etoposide-Platinum in First-Line Extensive-Stage SCLC: Results from the CASPIAN Study

N. Reinmuth, N. Shire, Haiyi Jiang, 2019, Journal of Thoracic Oncology.

a of Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN):

N. Reinmuth, N. Shire, Haiyi Jiang, 2020 .

Impact of abiraterone acetate plus prednisone in patients with castration-sensitive prostate cancer and visceral metastases over four years of follow-up: A post-hoc exploratory analysis of the LATITUDE study.

K. Fizazi, K. Chi, G. Leitz, 2021, European journal of cancer.

Five-Year Survival Outcomes From the PACIFIC Trial: Durvalumab After Chemoradiotherapy in Stage III Non–Small-Cell Lung Cancer

D. Planchard, C. Faivre-Finn, S. Senan, 2022, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

O-12 KEYNOTE-061: Response to subsequent therapy following second-line pembrolizumab or paclitaxel in patients with advanced gastric or gastroesophageal junction adenocarcinoma

C. Fuchs, M. Mandalà, C. Shih, 2020 .

Primary Osteosarcoma of the Heart: Experience of an Unusual Case

M. Özgüroğlu, F. Selçukbiricik, S. Dervışoğlu, 2013, Case Reports in Oncology.

Survival with Olaparib in Metastatic Castration-Resistant Prostate Cancer.

F. Saad, N. Agarwal, C. Corcoran, 2020, The New England journal of medicine.

Olaparib tolerability and common adverse-event management in patients with metastatic castration-resistant prostate cancer: Further analyses from the PROfound study.

C. Gedye, M. Carducci, G. Gravis, 2022, European journal of cancer.

Receptor Expression Discrepancy between Primary and Metastatic Breast Cancer Lesions

M. Özgüroğlu, M. Ozturk, Ş. İlvan, 2014, Oncology Research and Treatment.

Pembrolizumab versus paclitaxel for previously treated patients with PD-L1–positive advanced gastric or gastroesophageal junction cancer (GC): Update from the phase III KEYNOTE-061 trial.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020 .

Phase I/II study of spartalizumab (PDR001), an anti-PD1 mAb, in patients with advanced melanoma or non-small cell lung cancer.

P. Ascierto, A. Fasolo, J. Mataraza, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Overall Survival with Durvalumab after Chemoradiotherapy in Stage III NSCLC

D. Planchard, C. Faivre-Finn, L. Paz-Ares, 2018, The New England journal of medicine.

Patient-reported outcomes with durvalumab by PD-L1 expression and prior chemoradiotherapy-related variables in unresectable, stage III non-small-cell lung cancer.

D. Planchard, C. Faivre-Finn, S. Senan, 2021, Future oncology.

Patient‐reported outcomes with cemiplimab monotherapy for first‐line treatment of advanced non–small cell lung cancer with PD‐L1 of ≥50%: The EMPOWER‐Lung 1 study

I. Bondarenko, C. Ivanescu, V. Mastey, 2022, Cancer.

Avelumab versus docetaxel in patients with platinum-treated advanced non-small-cell lung cancer (JAVELIN Lung 200): an open-label, randomised, phase 3 study.

Keunchil Park, F. de Marinis, M. Krzakowski, 2018, The Lancet. Oncology.

Intrapleural administration of interleukin‐2 for the treatment of patients with malignant pleural mesothelioma

N. Vogelzang, T. Karrison, G. Demir, 1998, Cancer.

Role of the antiangiogenetic drug paclitaxel on healing of intestinal anastomosis: an experimental study

M. Özgüroğlu, G. Dogusoy, A. Cengiz, 2005, Techniques in Coloproctology.

Abiraterone acetate plus prednisone in patients with newly diagnosed high-risk metastatic castration-sensitive prostate cancer (LATITUDE): final overall survival analysis of a randomised, double-blind, phase 3 trial.

D. Ye, B. Alekseev, K. Fizazi, 2019, The Lancet. Oncology.

A Randomized Phase II Study of Anti-CSF1 Monoclonal Antibody Lacnotuzumab (MCS110) Combined with Gemcitabine and Carboplatin in Advanced Triple-Negative Breast Cancer

Sung-Bae Kim, R. Greil, S. Kuemmel, 2021, Clinical Cancer Research.

Primary Gastric Lymphoma: Conservative Treatment Modality Is Not Inferior to Surgery for Early-Stage Disease

B. Ferhanoğlu, O. Eliçin, N. Beşe, 2012, ISRN oncology.

Abiraterone plus Prednisone in Metastatic, Castration‐Sensitive Prostate Cancer

Y. Park, D. Ye, B. Alekseev, 2017, The New England journal of medicine.

Intrathoracic Extravasation of Antineoplastic Agents: Case Report and Systematic Review

C. Akman, M. Özgüroğlu, N. Mandel, 2003, American journal of clinical oncology.

Pembrolizumab versus paclitaxel for previously treated, advanced gastric or gastro-oesophageal junction cancer (KEYNOTE-061): a randomised, open-label, controlled, phase 3 trial

Kazuhiro Yoshida, A. Benson, Y. Bang, 2018, The Lancet.

Cemiplimab monotherapy for first-line treatment of advanced non-small-cell lung cancer with PD-L1 of at least 50%: a multicentre, open-label, global, phase 3, randomised, controlled trial

G. Yancopoulos, N. Rizvi, I. Lowy, 2021, The Lancet.

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

H. Turna, M. Özgüroğlu, D. Tural, 2014, British Journal of Cancer.

KEYNOTE-590: Phase III study of first-line chemotherapy with or without pembrolizumab for advanced esophageal cancer.

M. Shah, P. Enzinger, B. Cho, 2019, Future oncology.

A Challenging Task: Identifying Patients with Cancer of Unknown Primary (CUP) According to ESMO Guidelines: The CUPISCO Trial Experience

H. Moch, A. Krämer, L. Mileshkin, 2021, The oncologist.

The Impact of Hybrid Capture-Based Comprehensive Genomic Profiling on Treatment Strategies in Patients with Solid Tumors

A. Bilici, G. Demir, M. Özgüroğlu, 2022, Journal of Oncological Sciences.

Deep, rapid, and durable prostate-specific antigen decline with apalutamide plus androgen deprivation therapy is associated with longer survival and improved clinical outcomes in TITAN patients with metastatic castration-sensitive prostate cancer.

B. H. Chung, A. Bjartell, K. Chi, 2023, Annals of oncology : official journal of the European Society for Medical Oncology.

Evaluating Alternative Ramucirumab Doses as a Single Agent or with Paclitaxel in Second-Line Treatment of Locally Advanced or Metastatic Gastric/Gastroesophageal Junction Adenocarcinoma: Results from Two Randomized, Open-Label, Phase II Studies

C. Tournigand, J. Ajani, M. Shah, 2022, Cancers.

Nivolumab in metastatic renal cell carcinoma: results from the Turkish Oncology Group Kidney Cancer Consortium database.

U. Demirci, B. Öksüzoğlu, M. Özgüroğlu, 2021, Future Oncology.

A Phase II Trial of Prexasertib (LY2606368) in Patients With Extensive-Stage Small-Cell Lung Cancer.

Melissa L. Johnson, L. Byers, A. Navarro, 2021, Clinical lung cancer.

Impact of subsequent immune checkpoint inhibitor treatment on overall survival with avelumab vs docetaxel in platinum-treated advanced NSCLC: Post hoc analyses from the phase 3 JAVELIN Lung 200 trial.

Keunchil Park, J. Vansteenkiste, J. Yang, 2021, Lung cancer.

Impact of prior chemoradiotherapy-related variables on outcomes with durvalumab in unresectable Stage III NSCLC (PACIFIC).

C. Faivre-Finn, S. Senan, L. Paz-Ares, 2020, Lung cancer.

Patient-reported outcomes with first-line durvalumab plus platinum-etoposide versus platinum-etoposide in extensive-stage small-cell lung cancer (CASPIAN): a randomized, controlled, open-label, phase III study.

N. Reinmuth, N. Shire, Haiyi Jiang, 2020, Lung cancer.

Durvalumab, with or without tremelimumab, plus platinum-etoposide versus platinum-etoposide alone in first-line treatment of extensive-stage small-cell lung cancer (CASPIAN): updated results from a randomised, controlled, open-label, phase 3 trial.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, The Lancet. Oncology.

External Validation of a Novel Risk Model in Patients With Favorable Risk Renal Cell Carcinoma Defined by International Metastatic Renal Cell Carcinoma Database Consortium (IMDC): Results From the Turkish Oncology Group Kidney Cancer Consortium (TKCC) Database.

U. Demirci, B. Öksüzoğlu, M. Özgüroğlu, 2022, Clinical genitourinary cancer.

Durvalumab, with or without tremelimumab, plus platinum-etoposide in first-line treatment of extensive-stage small-cell lung cancer: 3-year overall survival update from CASPIAN

H. Mann, M. Hochmair, L. Havel, 2022, ESMO open.

Impact of Brain Metastases on Treatment Patterns and Outcomes With First-Line Durvalumab Plus Platinum-Etoposide in Extensive-Stage SCLC (CASPIAN): A Brief Report

N. Reinmuth, Haiyi Jiang, L. Paz-Ares, 2022, JTO clinical and research reports.

Patient-reported outcomes with durvalumab after chemoradiotherapy in stage III, unresectable non-small-cell lung cancer (PACIFIC): a randomised, controlled, phase 3 study.

P. Dennis, B. Cho, Yiduo Zhang, 2019, The Lancet. Oncology.

Adult Paratesticular Myxofibrosarcoma: Report of a Rare Entity and Review of the Literature

B. Özkan, H. Durak, M. Özgüroğlu, 2005, International Urology and Nephrology.

M. Özgüroğlu, F. Demi̇relli̇, D. Cıkman, 2020, Tumori.

Impact of cabazitaxel on 2-year survival and palliation of tumour-related pain in men with metastatic castration-resistant prostate cancer treated in the TROPIC trial

B. Tombal, S. Oudard, G. Gravis, 2013, Annals of oncology : official journal of the European Society for Medical Oncology.

An Open-Label, Multinational, Multicenter, Phase IIIb Study with Subcutaneous Administration of Trastuzumab in Patients with HER2-Positive Early Breast Cancer to Evaluate Patient Satisfaction.

S. Ahmed, M. Özgüroğlu, I. Çiçin, 2022, European journal of breast health.

Everolimus Plus Exemestane vs Everolimus or Capecitabine Monotherapy for Estrogen Receptor–Positive, HER2-Negative Advanced Breast Cancer: The BOLERO-6 Randomized Clinical Trial

H. Burris, D. Yardley, G. Jerusalem, 2018, JAMA oncology.

Outcomes with durvalumab after chemoradiotherapy in stage IIIA-N2 non-small-cell lung cancer: an exploratory analysis from the PACIFIC trial

S. Senan, Y. Wu, H. Mann, 2022, ESMO open.

792PTREATMENT PATTERNS IN PATIENTS (PTS) WITH METASTATIC CASTRATION-RESISTANT PROSTATE CANCER (MCRPC) PREVIOUSLY TREATED WITH DOCETAXEL (DOC)-BASED CHEMOTHERAPY (CTX): PROXIMA.

S. Hitier, H. Akaza, G. Fountzilas, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

A. Benson, Y. Bang, C. Fuchs, 2021, Gastric Cancer.

Pembrolizumab versus paclitaxel for previously treated PD-L1-positive advanced gastric or gastroesophageal junction cancer: 2-year update of the randomized phase 3 KEYNOTE-061 trial

Y. Bang, C. Fuchs, E. Van Cutsem, 2021, Gastric Cancer.

Molecular determinants of clinical outcomes with pembrolizumab versus paclitaxel in a randomized, open-label, phase 3 trial in patients with gastroesophageal adenocarcinoma.

C. Fuchs, E. Van Cutsem, M. Mandalà, 2021, Annals of oncology : official journal of the European Society for Medical Oncology.

789PPROGNOSTIC FACTORS FOR SURVIVAL AND SEQUENCING OF LIFE-EXTENDING THERAPIES IN METASTATIC CASTRATION RESISTANT PROSTATE CANCER (MCRPC) PATIENTS (PTS) IN POST-DOCETAXEL (D) SETTING.

E. Esteban, J. Bellmunt, S. Oudard, 2014, Annals of oncology : official journal of the European Society for Medical Oncology.

Central, prospective detection of homologous recombination repair gene mutations (HRRm) in tumour tissue from >4000 men with metastatic castration-resistant prostate cancer (mCRPC) screened for the PROfound study

A. Kohlmann, C. Gedye, C. Corcoran, 2019, Annals of Oncology.

Spontaneous Improvement of Tardive Dystonia During Mania

M. Özgüroğlu, A. Üçok, O. Yazıcı, 1991, British Journal of Psychiatry.

Tolerability of abiraterone (abi) combined with olaparib (ola) in patients (pts) with metastatic castration-resistant prostate cancer (mCRPC): Further results from the phase III PROpel trial.

A. Armstrong, N. Clarke, C. Gedye, 2022, Journal of Clinical Oncology.

Clinical significance of p95HER2 overexpression, PTEN loss and PI3K expression in p185HER2-positive metastatic breast cancer patients treated with trastuzumab-based therapies

H. Turna, M. Özgüroğlu, D. Tural, 2014, British Journal of Cancer.

Phase II study of afatinib plus pembrolizumab in patients with squamous cell carcinoma of the lung following progression during or after first-line chemotherapy (LUX-Lung-IO).

Abidemi K. Adeniji, J. Riess, E. Felip, 2022, Lung cancer.

LBA54 Three years survival outcome and continued cemiplimab (CEMI) beyond progression with the addition of chemotherapy (chemo) for patients (pts) with advanced non-small cell lung cancer (NSCLC): The EMPOWER-Lung 1 trial

I. Lowy, M. Gumus, M. Schenker, 2022, Annals of Oncology.

Generalized telangiectasia as the major manifestation of angiotropic (intravascular) lymphoma

C. Baykal, M. Özgüroğlu, C. Baykal, 1997, The British journal of dermatology.

A randomized Phase III trial of etoposide, epirubicin, and cisplatin versus 5‐fluorouracil, epirubicin, and cisplatin in the treatment of patients with advanced gastric carcinoma

F. Tas, M. Özgüroğlu, H. Akbulut, 1998 .

Effect of antibiotic treatment on immune checkpoint inhibitors efficacy in patients with advanced non-small cell lung cancer.

G. Can, H. Turna, M. Özgüroğlu, 2023, Lung cancer.

Clinical Features and Prognostic Factors of Metastatic Non-Clear Cell Renal Cell Carcinoma: A Multicenter Study from the Turkish Oncology Group Kidney Cancer Consortium

B. Öksüzoğlu, M. Özgüroğlu, S. Kılıçkap, 2023, Urologia Internationalis.

First-line cemiplimab monotherapy and continued cemiplimab beyond progression plus chemotherapy for advanced non-small-cell lung cancer with PD-L1 50% or more (EMPOWER-Lung 1): 35-month follow-up from a mutlicentre, open-label, randomised, phase 3 trial

I. Lowy, I. Bondarenko, M. Schenker, 2023, The Lancet Oncology.

Efficacy and safety evaluation based on time from completion of radiotherapy to randomization with durvalumab or placebo in pts from PACIFIC.

C. Faivre-Finn, S. Senan, D. Raben, 2018, Annals of oncology : official journal of the European Society for Medical Oncology.

Durvalumab ± tremelimumab + platinum-etoposide in first-line extensive-stage SCLC (ES-SCLC): Updated results from the phase III CASPIAN study.

N. Reinmuth, Haiyi Jiang, N. Byrne, 2020, Journal of Clinical Oncology.

Apalutamide plus Androgen Deprivation Therapy for Metastatic Castration-Sensitive Prostate Cancer: Analysis of Pain and Fatigue in the Phase 3 TITAN Study

E. Basch, N. Agarwal, D. Ye, 2021, The Journal of urology.

Targeted treatment for unresectable EGFR mutation-positive stage III non-small cell lung cancer: Emerging evidence and future perspectives.

M. Özgüroğlu, I. Casarini, Terufumi Kato, 2023, Lung cancer.

The association of tissue tumor mutational burden (tTMB) using the Foundation Medicine genomic platform with efficacy of pembrolizumab versus paclitaxel in patients (pts) with gastric cancer (GC) from KEYNOTE-061.

Y. Bang, C. Fuchs, E. Van Cutsem, 2020 .

Durvalumab in Stage III Non-Small-Cell Lung Cancer.

S. Antonia, M. Özgüroğlu, 2018, The New England journal of medicine.

Olaparib for the Treatment of Patients With Metastatic Castration-Resistant Prostate Cancer and Alterations in BRCA1 and/or BRCA2 in the PROfound Trial

N. Agarwal, A. Barnicle, A. Thiery-Vuillemin, 2023, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

Symptomatic Pneumonitis With Durvalumab After Concurrent Chemoradiotherapy in Unresectable Stage III NSCLC

J. Naidoo, A. Villegas, C. Wadsworth, 2024, JTO clinical and research reports.

Tolerability of Olaparib Combined with Abiraterone in Patients with Metastatic Castration-resistant Prostate Cancer: Further Results from the Phase 3 PROpel Trial.

A. Degboe, M. Özgüroğlu, U. Emmenegger, 2024, European urology oncology.

Apalutamide (apa) for metastatic castration-sensitive prostate cancer (mcspc): Outcomes in high-volume (hv) and low-volume (lv) disease from the titan final analysis (fa)

N. Agarwal, A. Bjartell, A. Merseburger, 2021, European Urology.

Atezolizumab monotherapy versus chemotherapy in untreated locally advanced or metastatic urothelial carcinoma (IMvigor130): final overall survival analysis from a randomised, controlled, phase 3 study.

S. Mariathasan, M. Özgüroğlu, J. Arranz, 2023, The Lancet. Oncology.